Gilead Sciences, Inc. (GILD) to Post FY2017 Earnings of $6.86 Per Share, Gabelli Forecasts

Gilead Sciences, Inc. (NASDAQ:GILD) – Stock analysts at Gabelli issued their FY2017 earnings per share estimates for Gilead Sciences in a research note issued on Wednesday. Gabelli analyst J. He anticipates that the biopharmaceutical company will post earnings per share of $6.86 for the year. Gabelli currently has a “Buy” rating and a $85.00 target price on the stock.

Several other research analysts have also recently commented on the company. Vetr cut Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $74.88 price target on the stock. in a research note on Tuesday, April 25th. BMO Capital Markets reiterated a “hold” rating and issued a $76.00 price target (up previously from $75.00) on shares of Gilead Sciences in a research note on Wednesday, May 3rd. Maxim Group reiterated a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, May 3rd. Barclays PLC reiterated an “overweight” rating and issued a $85.00 price target on shares of Gilead Sciences in a research note on Wednesday, May 3rd. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $87.00 price target on shares of Gilead Sciences in a research note on Monday, April 24th. Eleven investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and two have assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $80.67.

Earnings History and Estimates for Gilead Sciences (NASDAQ:GILD)

TRADEMARK VIOLATION NOTICE: This article was originally posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://www.themarketsdaily.com/2017/05/20/gilead-sciences-inc-gild-to-post-fy2017-earnings-of-6-86-per-share-gabelli-forecasts-updated.html.

Gilead Sciences (NASDAQ:GILD) traded down 0.954% during trading on Monday, reaching $66.965. The company had a trading volume of 2,126,331 shares. The company has a market capitalization of $87.52 billion, a P/E ratio of 7.077 and a beta of 1.11. The firm’s 50 day moving average is $67.22 and its 200-day moving average is $71.12. Gilead Sciences has a 12 month low of $65.38 and a 12 month high of $88.85.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $2.20 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.18 by $0.02. Gilead Sciences had a return on equity of 92.36% and a net margin of 44.43%. The firm had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.66 billion.

Several hedge funds have recently bought and sold shares of the company. Bartlett & Co. LLC raised its stake in Gilead Sciences by 1.0% in the third quarter. Bartlett & Co. LLC now owns 338,282 shares of the biopharmaceutical company’s stock valued at $26,765,000 after buying an additional 3,330 shares during the last quarter. Grandfield & Dodd LLC raised its stake in Gilead Sciences by 1.0% in the third quarter. Grandfield & Dodd LLC now owns 8,643 shares of the biopharmaceutical company’s stock valued at $684,000 after buying an additional 82 shares during the last quarter. Chickasaw Capital Management LLC raised its stake in Gilead Sciences by 10.0% in the third quarter. Chickasaw Capital Management LLC now owns 22,100 shares of the biopharmaceutical company’s stock valued at $1,749,000 after buying an additional 2,000 shares during the last quarter. Solaris Asset Management LLC raised its stake in Gilead Sciences by 2.4% in the third quarter. Solaris Asset Management LLC now owns 38,621 shares of the biopharmaceutical company’s stock valued at $3,056,000 after buying an additional 894 shares during the last quarter. Finally, Regentatlantic Capital LLC raised its stake in Gilead Sciences by 3.2% in the third quarter. Regentatlantic Capital LLC now owns 58,265 shares of the biopharmaceutical company’s stock valued at $4,610,000 after buying an additional 1,796 shares during the last quarter. 74.19% of the stock is owned by institutional investors.

In other news, EVP Gregg H. Alton sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 30th. The shares were sold at an average price of $67.48, for a total transaction of $337,400.00. Following the completion of the sale, the executive vice president now owns 117,988 shares of the company’s stock, valued at $7,961,830.24. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction that occurred on Monday, April 3rd. The stock was sold at an average price of $67.18, for a total transaction of $4,926,510.94. Following the sale, the insider now directly owns 3,199,969 shares of the company’s stock, valued at approximately $214,973,917.42. The disclosure for this sale can be found here. 1.40% of the stock is owned by company insiders.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 29th. Shareholders of record on Friday, June 16th will be paid a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 3.08%. The ex-dividend date of this dividend is Wednesday, June 14th. Gilead Sciences’s dividend payout ratio is 18.91%.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

5 Day Chart for NASDAQ:GILD

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply